VIRX

Viracta Therapeutics, Inc. (VIRX) | Rumor.io

Viracta Therapeutics

VIRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VIRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 4

* Viracta Therapeutics, Inc. (VIRX) has been delisted from the NASDAQ exchange, according to the NASDAQ delisting list.
* Some investors are questioning the management of VIRX, citing a lack of transparency and fiduciary responsibility, and suggesting the company sell its assets or merge with another company.
* Nanatinostat, a drug candidate developed by VIRX, has shown promise with a similar mechanism of action to an FDA-approved drug for multiple myeloma.

Generated by AI

Sentiment

Of the messages about VIRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	50% -36.16
Bearish	—	—	—	50% +36.16

Bullish· Dec 5

The author believes Viracta Therapeutics has a high potential for growth, especially if it receives FDA approval or announces a compliance plan.
A news drop, such as an announcement of funding secured for a lymphoma or EBV targeting therapy, could significantly boost the stock price.
The company's progress in its pipeline and its ability to present a plan at an upcoming appeal hearing could also have a positive impact on the stock.

Bearish· Jul 24

The company's management has changed, with Bay City Capital taking over, following a failed program.
The stock has been heavily sold, with some individuals feeling like they're not alone in their losses.
The stock's price is expected to drop further, with some predicting a fall to $0.46 or even $0.40.

Generated by AI

Topics

Of the messages about VIRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Dec 5

$VIRX has bounced off VWAP and is holding strong, with a potential breakout above $0.30.
The asset is forming a bull flag on the daily chart, with a possible Elliot wave pattern indicating a second leg up.
A double bottom formation is possible, with a close and trading above $1.50 required to confirm, based on the monthly chart and historical price action.

Generated by AI

Community

Of the messages about VIRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	3.92%
Newcomers	—	—	—	96.08%

Regulars· Jul 24

The standard manipulation method of the company is still in effect, with the stock price being held in a 5-cent up/down wiggle area, specifically between 0.33-0.38 and 0.41-0.46, which has been a pattern for months.
The stock has shown potential to break through and move beyond the current price range, with some regulars speculating that it could reach $1 or more, and others expressing excitement and anticipation.
There is speculation and discussion about the company's business operations, with one regular mentioning a potential business opportunity (BO) that could result in a significant price increase to $4.00 per share, and another expressing frustration and disgust over the perceived manipulation of the stock price.

Newcomers· Feb 3

The company is considering a sale as part of a strategic review, and the CEO remains optimistic about the future approval of Nana-val.
The company has voluntarily closed its pivotal Phase 2 NAVAL-1 trial of Nana-val for relapsed/refractory EBV+ lymphomas, citing no new safety concerns.
The company is engaging in discussions for strategic alternatives with the goal of maximizing value, including potential alternatives such as a merger, licensing agreement, sale, or other strategic transaction.

Generated by AI

Also Discussed

Investors talking about VIRX also mention

#	Name	Attention
1	SEM - Select Medical Holdings Corporation	——
2	XOMA CorporationXOMA	0%0
3	NLTX - Neoleukin Therapeutics, Inc.	——
4	APTO - Aptose Biosciences Inc.	——
5	Indaptus Therapeutics Inc.INDP	0%0
6	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
7	YTEN - Yield10 Bioscience, Inc.	——
8	Leonardo DRS Inc.DRS	0%0
9	Element Solutions Inc.ESI	0%0
10	Cornerstone Building Brands IncCNR	0%new